Sustained Efficacy and Safety of Erenumab in Patients with Episodic Migraine who Failed 2–4 Prior Preventive Treatments: 2-year Interim Results of the LIBERTY Open-label Extension Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:
Nadia Tenenbaum, MD
Sr. Clinical Development Medical Director
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey
The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
1. Shi L, Lehto SG, Zhu DX, et al. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. The Journal of Pharmacology and Experimental Therapeutics 2016;356:223-231.
3. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018;392:2280-2287.